Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis

被引：0
|
作者：
Jin, Yinzhu [1 ]
Desai, Rishi J. [1 ]
Liu, Jun [1 ]
Choi, Nam-Kyong [1 ]
Kim, Seoyoung [1 ,2 ,3 ]
机构：
[1] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3094
引用
收藏
页数：3
相关论文
共 50 条
  • [31] PREFERENCES OF PATIENTS WITH RHEUMATOID ARTHRITIS REGARDING DISEASE MODIFYING ANTIRHEUMATIC DRUGS: A DISCRETE CHOICE EXPERIMENT
    Van Heuckelum, M.
    Mathijssen, E.
    Vervloet, M.
    Boonen, A.
    Pasma, A.
    Hebing, R.
    Vonkeman, H.
    Wenink, M.
    van den Bemt, B.
    van Dijk, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 188 - 189
  • [32] The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States
    Ding, Qian
    Shiltz, Dane
    Hossami, Dana
    Konieczny, Alison M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (08) : 1231 - 1241
  • [33] Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis
    Michael T. Nurmohamed
    Ben A. C. Dijkmans
    Drugs, 2005, 65 : 661 - 694
  • [34] POSTOPERATIVE COMPLICATIONS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGIC AND NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Pogozheva, E.
    Amirdzhanova, V.
    Makarov, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 374 - 375
  • [35] Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis
    Mutlu, Melek Yalcin
    Tascilar, Koray
    Schett, Georg
    JOINT BONE SPINE, 2023, 90 (05)
  • [36] Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Cho, Soo-Kyung
    Kim, Hyoungyoung
    Song, Yeo-Jin
    Kim, Hye Won
    Nam, Eunwoo
    Lee, Shin-Seok
    Lee, Hye-Soon
    Park, Sung-Hoon
    Lee, Yeon-Ah
    Park, Min-Chan
    Chang, Sung Hae
    Kim, Hyoun-Ah
    Kwok, Seung-Ki
    Kim, Hae-Rim
    Kim, Hyun-Sook
    Yoon, Bo Young
    Uhm, Wan-Sik
    Kim, Yong-Gil
    Kim, Jae Hoon
    Lee, Jisoo
    Choi, Jeongim
    Sung, Yoon-Kyoung
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (04): : 546 - +
  • [37] Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis
    Nurmohamed, MT
    Dijkmans, BAC
    DRUGS, 2005, 65 (05) : 661 - 694
  • [38] The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Ozen, Gulsen
    Pedro, Sofia
    Michaud, Kaleb
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (05) : 648 - 655
  • [39] Which Are The Most Common Disease Modifying Antirheumatic and Biologic Treatment Pathways For Rheumatoid Arthritis Patients?
    Pedro, Sofia
    Wolfe, Frederick
    O' Dell, James
    Michaud, Kaleb
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S721 - S721
  • [40] Factors predicting addition of disease-modifying antirheumatic drugs after initial methotrexate monotherapy in patients with rheumatoid arthritis
    Takashi Yamaguchi
    Noriko Kohyama
    Miki Takenaka
    Takahiro Okada
    Tatsuya Kurihara
    Kosuke Sakurai
    Yusuke Miwa
    Mari Kogo
    Clinical Rheumatology, 2021, 40 : 2657 - 2663
12345